October 2026 EMA/CHMP recommendations

Guggenheim maintained a Buy rating and $275 price target on Revolution Medicines (NASDAQ:RVMD) after the European Medicines Agency recommended approval of its drug Rasonque. The stock has risen 281% in the past year, though some analysts suggest it may be overvalued. Multiple firms have recently initiated coverage with positive ratings and price targets ranging from $226 to $318.

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target. The stock has gained 281% over the past year. The FDA approved Rasonque (daraxonrasib) for pancreatic cancer, with trials showing improved survival rates. Analysts cite strong early launch trends and commercial potential, though some note overvaluation. Multiple firms raised price targets following the approval.

Revolution Medicines (RVMD) announced the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for RASONQUE as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma. The recommendation is based on Phase 3 trial results showing RASONQUE improved overall survival (13.2 months vs. 6.7 months with chemotherapy) and progression-free survival (7.2 months vs. 3.6 months). The EMA's expedited review process was used.

Revolution Medicines (RVMD) received a positive CHMP opinion for RASONQUE in treating metastatic pancreatic cancer, based on Phase 3 trial results showing a 60% reduction in death risk. The EMA's opinion follows an expedited review and could lead to EU/EEA approval, expanding market access. The drug was previously approved in the US.

Revolution Medicines' (RVMD) RASONQUE showed a 60% reduction in death risk vs. chemotherapy in a Phase 3 trial for pancreatic cancer. The EMA's CHMP gave a positive opinion for its use in the EU. The drug is already FDA-approved in the U.S.